Previous 10 | Next 10 |
2024-02-20 16:14:18 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Citi downgrades Arvinas to neutral, cites valuation Pfizer, Arvinas...
- Sean Cassidy leaving Arvinas as of February 29, 2024 - - Randy Teel, Ph.D. to assume the role of interim Chief Financial Officer - NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of dru...
– ARV-102 is a novel oral PROTAC® protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2 (LRRK2) – – The Phase 1 trial of ARV-102 will evaluate safety, tolerability, pharmacokinetics, a...
2024-02-14 15:55:46 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Pfizer, Arvinas' breast cancer therapy gets FDA fast track status A...
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the first patient has been dosed in its Phase 1b/2 clinical trial evaluating the combination of samuracicl...
Shares of Arvinas, Inc. (NASDAQ: ARVN) traded at a new 52-week high today and are currently trading at $48.13. So far today, approximately 40,727 shares have been exchanged, as compared to an average 30-day volume of 573.77k shares. Arvinas, Inc., a clinical-stage biopharmaceutical company, e...
2024-02-06 07:03:50 ET More on Arvinas, Pfizer, etc. Pfizer: Simply Too Cheap To Ignore Pfizer Is Down 54% From Highs, Now Yields 6.1% Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market Pharma giants turn to China in search of targe...
-- Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC ® ) protein degrader designed to target and degrade the estrogen receptor (ER) protein -- NEW HAVEN, Conn. and NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE...
NEW HAVEN, Conn., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Ron Peck, M.D., Chief Medical Officer, and Randy Teel, Ph.D., Senior Vice President, C...
2024-02-01 15:42:17 ET More on Arvinas Arvinas: Positive Breast Cancer Data Leads To Other Developments Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Wells Fargo upgrades Arvinas to overweight ahead of Phase 3 data readout ...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...